ClinicalTrials.gg
Not yet recruitingNCT07276802TRIBECAUpdated Mar 31, 2026

The TRIBECA Study (TRIessence/Byqlovi for Easier CAtaract Surgery)

A Phase 4 interventional study of Triamcinolone (Optional) and control group in Post Cataract Surgery, sponsored by Research Insight LLC. Not yet recruiting at 1 site in United States. Open to participants aged 22 Years and older. Per ClinicalTrials.gov, last updated 2026-03-31.

Sponsored by Research Insight LLC · Phase 4, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
22 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 456 studies in Cataract with a site in United States — 49 open to participants now, 56 under way, 4 of them phase 3. Cataract · United States.

Planned enrollment
235th of 322
40 · median 100
Started
2026
with 20 others
Phase 4
86 of 456
7 open now
Primary completion
2026-12
later than 25 of 54 live
Registered
426th of 456
by date
Lead sponsor
8 of 456
Research Insight LLC

Among the 456 studies in Cataract with a site in United States, this one is the 235th largest by planned enrollment of the 322 interventional ones that give a count, is one of 21 that started in 2026, is one of 86 in phase 4, reaches primary completion later than 25 of the 54 other live ones, and was the 426th registered.

Cataract

1,632 studies on the registry are indexed under Cataract; 235 are open to participants now.

Browse Cataract studies →

Open to participants now

49 of the 456 studies in Cataract with a site in United States are open now. Recruiting first, the newest first:

44 more — sign in →

All 49 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 142 Cataract studies recruiting now, 88 (62%) set no upper age limit and 8 (6%) stop at 75 or younger; 10 take children under 18; 16 take healthy volunteers.

This study: 22 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 456 studies in Cataract with a site in United States, or all of them as a file.
02

Study summary

A self-controlled, prospective clinical study of the safety, clinical efficacy, and patient acceptance of subconjunctival delivery of triamcinolone 40 mg/mL (Triesence) at the conclusion of cataract surgery or topical clobetasol 0.05 (Byqlovi) BID for 14 days, with intracameral moxifloxacin 0.5%, and topical nepafenac 0.3% (Ilevro) for 14 days, as compared to traditional topical postoperative prednisolone acetate 1% QID, moxifloxacin 0.5% drops QID, and ketorolac 0.5% QID in controlling postoperative pain and inflammation in subjects undergoing sequential bilateral cataract surgery.

Read the detailed description

Drug delivery is one of the most exciting advances in ophthalmology, and with new products available comes the opportunity for an improved patient experience in cataract surgery. Frequent use of topical medications is associated with difficulty in application and compliance for many patients and create a burden for family members. In addition there is a cost to many patients that presents financial obstacles.

The purpose of this study is to evaluate the safety, effectiveness and patient acceptance of two post cataract surgery drug treatment regimens that minimize the use of topical medications. This will be a prospective evaluation of patients having routine, bilateral cataract surgery in which one eye of each subject will be randomized to receive a "conventional" regimen and the other eye will receive a regimen of "less drops". The "less drops" regimen will include EITHER (by randomization) a 0.1 cc subconjunctival injection of triamcinolone 40mg/mL (Triesence) at the end of surgery OR postoperative administration of topical clobetasol 0.05% (Byqlovi) BID for 14 days to deliver corticosteroid. Both steroid regimens will be delivered with nepafenac 0.3% QD for 14 days as a topical NSAID, and intracameral moxifloxacin 0.5% QID for 7 days as an antibiotic. The "conventional" topical medication regimen will include prednisolone acetate 1% QID, ketorolac 0.5% QID , and moxifloxacin 0.5% topical drops QID. With all of these treatment regimens, the patients will be receiving two on-label, FDA approved products and one (intracameral moxifloxacin) that is technically off-label but is so well accepted that it is used in approximately half the cataract surgery performed in the US. . In all patients the fellow eye will act as the control.

Patients will be evaluated at 1 day, 1 week and 1 month postoperatively. Measurements are listed in the visit schedule table below. Patients will also be subjectively asked about their symptoms of pain and photophobia and be asked about their acceptance, cost, and which treatment protocol they preferred.

03

Conditions studied

  • Post Cataract Surgery

Browse trials for

Keywords

  • Interventional Study Design
04

Who can participate

Ages eligible
22 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • A male or female subject in good general health, > 22 years of age at the time of the screening visit
  • A subject must be able to comprehend and willing to give
  • A woman of must not be pregnant or lactating.
  • A subject has the availability, willingness and sufficient cognitive awareness to comply with exam procedures and able to return for all scheduled study visits
  • A subject with a cataract for which routine phacoemulsification extraction and implantation of an intraocular lens has been planned
  • A subject with clear ocular media other than cataract in their scheduled operative eye
  • A subject with normal OCT of the macula in both eyes
  • A subject has the potential for a post-operative Snellen BCDVA of 20/30 or better in both eyes

Exclusion criteria

Exclusion Criteria:

  • A subject with a history of complications, adverse events, trauma or disease in the nasolacrimal area, whether or not it was due to punctal plug wear, including but not limited to dacryocystitis, inflammation or canaliculitis in either eye
  • A subject with any moderate to severe lid, conjunctival or corneal findings in either eye at the screening visit
  • A subject with any signs of intraocular inflammation (cells/flare) in either eye at the screening visit
  • A subject with a known sensitivity to any of the study medications.
  • A subject with a history as a responder or glaucoma
  • A subject with a known or suspected allergy or to non-steroidal anti-inflammatory drugs (NSAIDs), or to any component of the test article
  • A subject with only one eye with potentially good vision
  • A subject with a known pathology that may affect visual acuity (as determined by the Investigator); particularly retinal changes that affect vision (macular degeneration, cystoid macular edema, proliferative diabetic retinopathy, etc.) in their scheduled surgical eye
  • A subject that has a condition associated with the fluctuation of hormones that could lead to refractive changes
  • A subject with amblyopia or strabismus
  • A subject has a history of ocular trauma in their scheduled surgical eye
  • A subject that has undergone prior intraocular surgery in the scheduled surgical eye within the last 6 months or laser surgery within three months prior to screening
  • A subject with pupil abnormalities (non-reactive, tonic pupils, abnormally shaped pupils, or pupils that do not dilate at least 3.5 mm under mesopic/scotopic conditions) in their scheduled surgical eye.
  • A subject with a corneal abnormality (e.g., stromal, epithelial or endothelial dystrophies) that, in the best judgment of the investigator, is likely to interfere with the outcomes of the study
  • A subject with an inability to achieve keratometric stability for contact lens wearers
  • A subject with a history of chronic/recurrent inflammatory eye disease (e.g., scleritis, uveitis, herpes keratitis) in either eye
  • A subject with uncontrolled glaucoma
  • A subject that requires the use of systemic or ocular medications that may affect vision, ocular inflammation or pain
  • A subject with an acute or chronic disease, or illness, that would increase risk or confound study results (e.g., disease, connective tissue disease, , suspected glaucoma, glaucomatous changes in the fundus or visual field, other source of ocular inflammation, etc.)
  • A subject with an uncontrolled systemic disease: A potential subject in whom therapy for a systemic disease is not yet stabilized will not be considered for entry into the study
  • A subject with diabetes that is poorly controlled
  • A subject currently participating or has participated in another clinical trial within 30 days prior to enrollment.

Intra-Operative Exclusion Criteria (Surgical Complications):

  • Sulcus-sulcus or bag-sulcus fixation
  • Posterior capsular rupture or zonular dialysis
  • Disruption of anterior hyaloid face
  • Vitreous loss
  • Floppy iris syndrome
  • Inability to place IOL in capsular bag
  • Significant anterior chamber hyphema
  • Significant zonular rupture.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Experimental Group

    Triesence or Byqlovi Arm with nepafenac

    Drug: Triamcinolone (Optional)

  • Active comparator
    Control Group

    Topical Moxifloxacin, Ketorolac, Prednisolone Acetate

    Drug: control group

Interventions

  • triamcinolone 40mg/ml or topical clobetasol 0.05% with nepafenac 0.3% QD for 14 days

    Also known as: clobetasol

  • Drugcontrol group

    topical medication regimen will include prednisolone acetate 1% QID, ketorolac 0.5% QID, and moxifloxacin 0.5% topical drops QID.

06

What researchers measure

Primary outcomes

  1. Primary

    Patient Preference Between Medication Protocols (COMTOL Questionnaire Question 1)

    Time frame: 14 days after cataract surgery in each eye

  2. Primary

    Patient preference for medication protocol between the two eyes, as reported based on the question, "Thinking about your overall experience taking medications in each eye after surgery, which eye did you prefer?" (question 1 from validated COMTOL questionnaire)

    Time frame: 14 days after cataract surgery in each eye

Secondary outcomes

  1. Patient-Reported Postoperative Ocular Pain Severity Using a 0-10 Visual Analog Scale

    Study subject evaluation of post-op ocular pain using a visual analog scale with pain ranking from 0 to 10 (10 high) with the request, "Please rate the severity of discomfort caused by your eye medicines at their worst point."

    Time frame: 14 days after cataract surgery in each eye

Other outcomes

  1. Summed Ocular Inflammation Score at One Week (Anterior Chamber Cells + Flare)

    Summed Ocular Inflammation Score (sum of the mean anterior chamber cells and anterior flare score) at one week.

    Time frame: 7 days after cataract surgery in each eye

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Apr 2026; primary completion for Dec 2026, 8 months later.

Of 46 phase 4 interventional studies under Cataract, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 34. This study's planned 8 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 30, 2025
First posted
Dec 11, 2025
StartEst.
Apr 1, 2026
Primary completionEst.
Dec 31, 2026
CompletionEst.
Jan 31, 2027
Last update
Mar 31, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 31, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07276802
Lead sponsor
Research Insight LLC
Responsible party
Sponsor
First posted
Dec 11, 2025
Start date
Apr 1, 2026 (estimated)
Primary completion
Dec 31, 2026 (estimated)
Completion
Jan 31, 2027 (estimated)
Last update
Mar 31, 2026

Study contacts

John Hovanesian, MD
Contact
jhovanesian@researchinsight.com
949-951-2020
Leslie Lemieux, MHA
Contact
research@researchinsightca.com

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Triamcinolone

Start the discussion